Details for Patent: 11,786,508

« Back to Dashboard

Which drugs does patent 11,786,508 protect, and when does it expire?

Patent 11,786,508 protects IGALMI and is included in one NDA.

This patent has forty patent family members in twenty countries.

Summary for Patent: 11,786,508

Title:	Use of sublingual dexmedetomidine for the treatment of agitation
Abstract:	The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
Inventor(s):	Krishnan Nandabalan, Frank Yocca, Sameer Sharma, Harsh NEGI, Deepa Saini
Assignee:	Bioxcel Therapeutics Inc , Bioxcel LLC
Application Number:	US17/990,312
Patent Claim Types: see list of patent claims	Use; Dosage form;

United States Patent 11,786,508: Dexmedetomidine Oral Film Patent Scope, Claims, Exclusivity and Patent Landscape

U.S. Patent No. 11,786,508 protects a narrowly defined method of treating agitation associated with schizophrenia using a 60-microgram dose of dexmedetomidine delivered as a water-soluble oral film. The claim requires administration to the oral mucosa, an anti-agitation effect within about 60 minutes, and no significant sedation. Sublingual and buccal administration are separately claimed.

The patent is commercially relevant to IGALMI, BioXcel Therapeutics’ dexmedetomidine sublingual film approved for acute agitation associated with schizophrenia or bipolar disorder in adults. The patent does not broadly cover all dexmedetomidine products, all oral films, or all treatments for agitation.

What does U.S. Patent 11,786,508 protect?

The patent protects a treatment method with multiple cumulative limitations. A potentially infringing product or use must satisfy each required element of claim 1, either literally or under the doctrine of equivalents.

Claim element	Required scope
Patient	An agitated subject with schizophrenia
Condition excluded	Agitation cannot be perioperative agitation
Active ingredient	Dexmedetomidine or a pharmaceutically acceptable salt
Dose	One or two single-dose administrations of 60 micrograms
Route	Administration to the oral mucosa
Dosage form	Solid, water-soluble dosage form
Delivery system	Film
Clinical result	Anti-agitation effect in less than about 60 minutes
Safety result	No significant sedation after administration

The claim is a method-of-treatment claim, not a composition claim. It does not independently claim the chemical compound dexmedetomidine, dexmedetomidine hydrochloride as a molecule, or every formulation containing the active ingredient.

The “consisting of” transition is important. It limits the claimed method to the recited administration framework. The claim does not necessarily exclude ordinary excipients or routine clinical steps, but additional administration steps or materially different treatment protocols could create noninfringement arguments.

How narrow is the 60-microgram dexmedetomidine limitation?

The 60-microgram limitation is a central narrowing feature. Claim 1 requires “one or two single dosage administrations of 60 micrograms.” The language can be read to cover either:

1. One 60-microgram administration; or
2. Two separate 60-microgram administrations.

A regimen using a 120-microgram film may fall outside the literal scope of this claim, even if it uses the same active ingredient, route and film technology. The analysis would depend on the exact product and whether another patent claim covers the higher-dose regimen.

The patent therefore has greater direct relevance to a 60-microgram product or a treatment protocol that uses a 60-microgram dose than to products administered only at 120 or 180 micrograms.

What do claims 2 through 6 add?

Claim	Additional limitation	Commercial significance
2	Sublingual administration	Directly targets sublingual film delivery
3	Buccal administration	Covers placement against the cheek or buccal mucosa
4	Dexmedetomidine hydrochloride	Narrows the active ingredient to the hydrochloride salt
5	Acute agitation	Covers acute agitation in a schizophrenia patient
6	Chronic agitation	Covers chronic agitation in a schizophrenia patient

Claims 2 and 3 are alternative route claims. A sublingual product may implicate claim 2, while a product designed for buccal absorption may implicate claim 3. Claim 4 is narrower than claim 1 because it specifies dexmedetomidine hydrochloride.

Claims 5 and 6 expand the clinical characterization of the agitation to acute or chronic agitation. Claim 5 is commercially more significant because the FDA-approved use of IGALMI is acute treatment of agitation. Claim 6 is broader from a disease-duration perspective but may be more difficult to apply to the approved label if chronic agitation is not an approved indication.

What formulations are protected by U.S. Patent 11,786,508?

The patent protects a solid, water-soluble film containing dexmedetomidine or its pharmaceutically acceptable salt when used in the claimed treatment method.

The claims do not expressly require a particular polymer, plasticizer, flavoring agent, backing layer, manufacturing process, film thickness or dissolution time. Those features may be addressed in related patents or unasserted claim scope in the same family.

The patent does not cover, based on the quoted claims alone:

• Intravenous dexmedetomidine;
• Intramuscular dexmedetomidine;
• Oral tablets or capsules;
• Injectable perioperative use;
• A transdermal patch;
• A nebulized product;
• A dexmedetomidine film used for a condition other than the claimed schizophrenia-associated agitation;
• A film that is not solid and water-soluble;
• A regimen that does not use one or two 60-microgram administrations.

A competing product could seek design-around protection by changing the dose, dosage form, route, indication, release profile or active ingredient salt. A design-around would still need to be evaluated against related patents in the dexmedetomidine film family.

How does the patent compare with the FDA-approved IGALMI product?

IGALMI is a sublingual film containing dexmedetomidine hydrochloride. The FDA approved IGALMI in April 2022 for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.[1]

The approved product and claim 1 overlap in several respects:

IGALMI characteristic	Patent claim 1
Dexmedetomidine hydrochloride	Dexmedetomidine or salt
Sublingual film	Oral mucosal film
Acute agitation	Covered by dependent claim 5
Schizophrenia-associated agitation	Expressly required
Rapid onset	Effect required in less than about 60 minutes
Sedation profile	Claim requires no significant sedation
60-microgram dose	Covered by claim 1

The patent claim is narrower than the FDA label because claim 1 is limited to a patient with schizophrenia and a 60-microgram administration. The FDA label covers schizophrenia and bipolar disorder and permits dose selection based on the severity of agitation.[1]

A commercial challenge to IGALMI would therefore need to examine the full Orange Book patent listing, not only Patent No. 11,786,508.

What is the Orange Book and FDA exclusivity status?

IGALMI is an FDA-approved small-molecule drug product. It is not a biologic and therefore does not receive biosimilar protection under the Public Health Service Act.

The product received five-year new chemical entity exclusivity beginning on its approval date, April 5, 2022. That exclusivity generally blocks submission of an abbreviated new drug application containing a Paragraph IV certification until four years after approval, subject to statutory exceptions. The five-year period is expected to run through April 5, 2027.[1][2]

The principal regulatory dates are:

Event	Date
FDA approval of IGALMI	April 5, 2022
Four-year NCE filing barrier	April 5, 2026
Five-year NCE exclusivity end	April 5, 2027
Potential ANDA launch date	Controlled by patents, litigation and exclusivity

Patent expiration and regulatory exclusivity are separate. Expiration of NCE exclusivity does not eliminate unexpired Orange Book patents. Conversely, a patent challenge may not permit launch while NCE exclusivity remains in effect.

When does dexmedetomidine film exclusivity expire?

U.S. Patent No. 11,786,508 was issued on December 26, 2023.[3] Its effective patent term is governed by the relevant priority chain, prosecution history and any terminal disclaimer. The patent’s expiration date should be assessed together with the related patents listed for IGALMI in the FDA Orange Book.

The commercially relevant exclusivity horizon for the IGALMI film platform extends beyond the 2027 NCE exclusivity date because related formulation and method-of-use patents may remain in force into the 2030s. A practical launch analysis should use the latest enforceable patent covering the proposed generic’s formulation, method of use or product characteristics.

Exclusivity layer	Relevance
NCE exclusivity	Delays ANDA approval and Paragraph IV timing
Method-of-use patents	Can cover treatment of agitation in defined patient groups
Film formulation patents	Can cover the sublingual or buccal dosage form
Product-by-process or manufacturing patents	May create additional barriers if the generic uses the same process
Regulatory labeling	Determines whether a proposed use is carved out or directly exposed

The quoted claims alone do not establish the complete expiration profile of the patent family. The issued patent, related family members, terminal disclaimers and Orange Book entries must be read together.

What Paragraph IV challenges could target this patent?

A Paragraph IV challenge could attack the listed patent on several grounds:

1. Noninfringement. A proposed product could use a different dose, route, dosage form, indication or treatment protocol.
2. Invalidity for anticipation. A challenger could argue that an earlier reference disclosed the complete combination of dexmedetomidine, 60 micrograms, oral mucosal film, rapid anti-agitation effect and reduced sedation.
3. Invalidity for obviousness. The challenger could combine prior art concerning dexmedetomidine, oral films, sublingual delivery and treatment of agitation.
4. Indefiniteness. The phrases “significant sedation,” “anti-agitation effect” and “less than about 60 minutes” could be challenged if the specification and prosecution history do not provide sufficiently objective boundaries.
5. Written description or enablement. A challenger could argue that the specification does not support the full range of schizophrenia-associated acute and chronic agitation covered by the claims.

The strongest noninfringement position would likely involve a product that does not use a 60-microgram film or does not carry a label directing treatment of schizophrenia-associated agitation. The strongest validity issues concern the result limitations and the combination of dose, route, formulation and clinical effect.

How strong is the patent estate?

Patent strength is mixed by claim type.

Stronger features

The claim combines several concrete limitations:

• A defined active ingredient;
• A specific 60-microgram dose;
• A solid, water-soluble film;
• Oral mucosal administration;
• A schizophrenia-associated agitation population;
• A rapid anti-agitation result.

This combination can make a single-reference anticipation challenge difficult if no prior art discloses all limitations together.

Vulnerable features

The claims include functional and clinical limitations that may create litigation risk:

• “Without also causing significant sedation”;
• “Produces an anti-agitation effect”;
• “In less than about 60 minutes”;
• “Acute agitation” and “chronic agitation.”

These terms may require clinical or pharmacodynamic evidence. The patent holder would likely need to prove that the accused regimen produces the claimed result and that the relevant sedation threshold is met.

The “about” language provides some tolerance around 60 minutes, but it does not establish an unlimited time period. The specification, examples and prosecution history would likely control the scope of that phrase.

What manufacturing and intellectual-property barriers affect competitors?

A competitor must solve more than the active ingredient problem. Dexmedetomidine hydrochloride is an established active pharmaceutical ingredient, so the principal barriers are likely to involve:

• Uniform loading of a low-dose active ingredient into a thin film;
• Stability during storage;
• Consistent sublingual dissolution;
• Taste masking;
• Mechanical strength during packaging and handling;
• Dose uniformity at 60 micrograms;
• Control of absorption and onset;
• Avoidance of excessive sedation or cardiovascular effects;
• Clinical evidence supporting the proposed agitation indication.

A generic tablet or injectable product would not necessarily compete directly with IGALMI because the commercial value lies in rapid oral mucosal administration and use in an agitated patient who may resist swallowing or intravenous access.

Are there biosimilar risks?

There is no biosimilar pathway for IGALMI. Dexmedetomidine is a small molecule, and a competitor would use the ANDA pathway for a therapeutically equivalent generic, or a 505(b)(2) application for a product with differences requiring reliance on some of the reference product’s findings.

A 505(b)(2) applicant could face patent certification obligations and method-of-use patent exposure. A product with a different film design, dose or administration route may require new clinical or bridging evidence.

What licensing deals affect the patent landscape?

The patent and FDA records identify BioXcel Therapeutics and its affiliates as the commercial developers associated with IGALMI. The quoted patent claims do not establish a third-party license, royalty arrangement or field-of-use restriction. Dexmedetomidine itself is an established active ingredient, so the principal commercial rights concern the film formulation, delivery technology, clinical use and regulatory product.

No licensing conclusion should be drawn from ownership of the active ingredient or from the FDA reference listing alone. Patent ownership, FDA application ownership and commercialization rights can be held by different entities.

What patent litigation and settlement agreements affect generic entry?

U.S. Patent No. 11,786,508 is a post-approval patent and may be relevant to any Paragraph IV notice involving an Orange Book-listed IGALMI patent. The commercial effect of a challenge would depend on:

• The specific patents certified in the ANDA;
• The date of Paragraph IV notice;
• Whether the patent holder files suit within 45 days;
• Whether a 30-month stay applies;
• Any first-filer exclusivity;
• The final judgment or settlement terms;
• Whether the settlement includes a licensed entry date.

The patent number alone does not establish a litigation outcome or settlement date. A definitive litigation assessment must distinguish district-court docket activity, Federal Circuit appeals, USPTO post-grant proceedings and private settlement agreements.

What generic launch scenarios exist?

Scenario	Likely consequence
No Paragraph IV challenge	Launch generally waits until relevant patents and exclusivity expire
Paragraph IV with no timely suit	FDA approval may proceed after statutory certification requirements
Paragraph IV with timely suit	Approval may be delayed by the 30-month stay or court resolution
Noninfringing 505(b)(2) product	May launch with a different route, dose or indication if regulatory and patent barriers are cleared
Carved-out label	May reduce method-of-use exposure but cannot remove formulation-patent risk
Patent invalidation	Could accelerate entry if no other listed patent blocks approval
Settlement	Entry date depends on the negotiated terms

The most credible early-entry strategy would likely involve a formulation or labeling design-around rather than a direct copy of the 60-microgram sublingual film.

Key Takeaways

• U.S. Patent No. 11,786,508 is a narrow method patent covering 60-microgram dexmedetomidine oral films for agitation in schizophrenia.
• Sublingual and buccal delivery are separately claimed.
• The claim requires a rapid anti-agitation effect and no significant sedation.
• The patent does not broadly cover dexmedetomidine, all oral films or all agitation treatments.
• IGALMI overlaps materially with the claimed sublingual film use, particularly for schizophrenia-associated acute agitation.
• FDA five-year NCE exclusivity began April 5, 2022, with the principal NCE barrier extending to April 5, 2027.
• Generic risk depends on the complete Orange Book patent family, not Patent No. 11,786,508 alone.
• The most important validity questions concern obviousness, functional result limitations and the definiteness of “significant sedation” and “less than about 60 minutes.”
• There is no biosimilar pathway because dexmedetomidine is a small molecule.
• A viable competitor would need to address film technology, dose uniformity, rapid mucosal delivery, clinical safety and patent-family coverage.

FAQs About U.S. Patent 11,786,508

Does U.S. Patent 11,786,508 cover 120-microgram IGALMI?

Not directly based on the quoted claim. Claim 1 specifies one or two 60-microgram administrations. A 120-microgram single administration may require analysis under other patents or claims in the family.

Does the patent cover buccal dexmedetomidine film?

Yes. Dependent claim 3 expressly recites buccal administration, provided all limitations of claim 1 are also satisfied.

Does the patent cover intravenous dexmedetomidine for agitation?

No. The claims require administration to the oral mucosa in a solid, water-soluble film.

Can a generic avoid the patent by using a tablet?

Potentially, with respect to this patent. A tablet would not satisfy the solid water-soluble film limitation, but other patents, regulatory requirements and infringement theories could remain relevant.

Is Patent No. 11,786,508 the only patent protecting IGALMI?

No. The complete IGALMI estate includes related formulation and method-of-use patents. The Orange Book listing and the full patent family must be reviewed to determine the controlling patent-expiration date.

References

1. U.S. Food and Drug Administration. (2022). IGALMI (dexmedetomidine hydrochloride) sublingual film prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. United States Patent and Trademark Office. (2023). U.S. Patent No. 11,786,508, methods of treating agitation. USPTO.

Drugs Protected by US Patent 11,786,508

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bioxcel	IGALMI	dexmedetomidine hydrochloride	FILM;BUCCAL, SUBLINGUAL	215390-001	Apr 5, 2022		RX	Yes	Yes						ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA BY SUBLINGUAL OR BUCCAL ADMINISTRATION
Bioxcel	IGALMI	dexmedetomidine hydrochloride	FILM;BUCCAL, SUBLINGUAL	215390-002	Apr 5, 2022		RX	Yes	No						ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA BY SUBLINGUAL OR BUCCAL ADMINISTRATION

International Family Members for US Patent 11,786,508

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017388759
Australia	2022200892
Australia	2024219731
Brazil	112019013503